X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GSK PHARMA ALEMBIC PHARMA/
GSK PHARMA
 
P/E (TTM) x 26.6 60.1 44.3% View Chart
P/BV x 6.1 11.8 51.5% View Chart
Dividend Yield % 0.8 2.1 37.1%  

Financials

 ALEMBIC PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
GSK PHARMA
Mar-16
ALEMBIC PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs7923,850 20.6%   
Low Rs4432,966 14.9%   
Sales per share (Unadj.) Rs167.0332.3 50.3%  
Earnings per share (Unadj.) Rs38.244.3 86.1%  
Cash flow per share (Unadj.) Rs42.047.2 88.9%  
Dividends per share (Unadj.) Rs4.0050.00 8.0%  
Dividend yield (eoy) %0.61.5 44.2%  
Book value per share (Unadj.) Rs84.9202.7 41.9%  
Shares outstanding (eoy) m188.5284.70 222.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.710.3 36.0%   
Avg P/E ratio x16.276.9 21.0%  
P/CF ratio (eoy) x14.772.2 20.4%  
Price / Book Value ratio x7.316.8 43.3%  
Dividend payout %10.5112.9 9.3%   
Avg Mkt Cap Rs m116,383288,643 40.3%   
No. of employees `000NA4.6 0.0%   
Total wages/salary Rs m4,2144,434 95.0%   
Avg. sales/employee Rs ThNM6,104.5-  
Avg. wages/employee Rs ThNM961.6-  
Avg. net profit/employee Rs ThNM813.7-  
INCOME DATA
Net Sales Rs m31,48728,148 111.9%  
Other income Rs m551,218 4.5%   
Total revenues Rs m31,54229,366 107.4%   
Gross profit Rs m10,0604,774 210.7%  
Depreciation Rs m722248 291.2%   
Interest Rs m370-   
Profit before tax Rs m9,3565,744 162.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m026 0.0%   
Tax Rs m2,1602,018 107.0%   
Profit after tax Rs m7,1943,752 191.7%  
Gross profit margin %31.917.0 188.4%  
Effective tax rate %23.135.1 65.7%   
Net profit margin %22.813.3 171.4%  
BALANCE SHEET DATA
Current assets Rs m15,06621,462 70.2%   
Current liabilities Rs m7,67410,536 72.8%   
Net working cap to sales %23.538.8 60.5%  
Current ratio x2.02.0 96.4%  
Inventory Days Days6768 99.0%  
Debtors Days Days4116 247.5%  
Net fixed assets Rs m8,2374,717 174.6%   
Share capital Rs m377847 44.5%   
"Free" reserves Rs m15,41616,308 94.5%   
Net worth Rs m16,00517,171 93.2%   
Long term debt Rs m016 0.0%   
Total assets Rs m24,59430,620 80.3%  
Interest coverage x255.2NM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 139.3%   
Return on assets %29.412.3 239.9%  
Return on equity %44.921.9 205.7%  
Return on capital %58.733.6 174.8%  
Exports to sales %55.70 392,239.7%   
Imports to sales %10.415.1 69.3%   
Exports (fob) Rs m17,5514 438,770.0%   
Imports (cif) Rs m3,2834,237 77.5%   
Fx inflow Rs m17,811519 3,431.7%   
Fx outflow Rs m5,3188,320 63.9%   
Net fx Rs m12,493-7,801 -160.1%   
CASH FLOW
From Operations Rs m9,3041,386 671.5%  
From Investments Rs m-3,1055,010 -62.0%  
From Financial Activity Rs m-1,959-6,383 30.7%  
Net Cashflow Rs m4,24012 35,932.2%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 2.9 10.2 28.4%  
FIIs % 9.1 23.8 38.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 15.4 90.3%  
Shareholders   49,328 102,036 48.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TORRENT PHARMA  NATCO PHARMA  CIPLA  GLENMARK PHARMA  VENUS REMEDIES  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS